PMC:7296049 / 22685-23677 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7296049","sourcedb":"PMC","sourceid":"7296049","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7296049","text":"Figure 3 Dl-3-n-butylphthalide (NBP) attenuates demyelination in corpus callosum after 2VO. (A) Representative images of luxol fast blue (LFB) staining in the corpus callosum at 2 weeks and 4 weeks after 2VO. Bar = 50 μm (n = 3 in each group). (B) Western blot analysis of the expressions of MBP (n = 6 in each group). (C) Myelin density in each group presented by the percentage of stained area in total area of corpus callosum. (D) Quantitative analysis of protein levels of MBP. β-actin was used as an internal control. (E) Quantitative analysis of mRNA levels of MBP. β-actin was used as an internal control (n = 6 in each group). ***p \u003c 0.001, the model group vs. the sham group; #p \u003c 0.05, ##p \u003c 0.01, ###p \u003c 0.001, the NBP60 group or NBP120 group vs. the model group; $p \u003c 0.05, $$$p \u003c 0.001, the NBP60 group vs. NBP120 group; and \u0026p \u003c 0.05, the model group sacrificed at 2 weeks vs. the model group sacrificed at 4 weeks. Values are expressed as mean ± SD. MBP, myelin basic protein.","divisions":[{"label":"label","span":{"begin":0,"end":8}}],"tracks":[]}